• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

Caerulomycin A Against Cancer

July 22, 2024

Caerulomycin A is a microbial metabolite isolated from marine actinomycetes. The chemical structure consists of a 2,2′-bypyridine core, which is similar to a biphenyl core. Because of this similarity, it is thought that it may bind well to tubulins and DNA topoisomerase, and thereby provide a potent anti-cancer affect.

In vitro and in vivo studies have shown caerulomycin A to be effective against paclitaxel-resistant cancer. In a study at Ohio University, several types of human tumor cell lines were prepared in vitro and treated with caerulomycin A and in combination with paclitaxel. The melanoma cells were also injected subcutaneously into a mouse model for in vivo study. The mice were then administered caerulomycin A by intraperitoneal injections.

The in vitro studies showed the growth of all cancer types was inhibited, including the paclitaxel-resistant cancer cells. The animal model was also effective and confirmed a significant reduction in tumor size.

The results of this study suggest a synergistic effect when used in combination with paclitaxel against several cancer types. Further work with caerulomycin A and related compounds may offer a new strategy for cancer treatment.

Tong L, Sun W, Wu S, et al. Characterization of caerulomycin A as a dual-targeting anticancer agent. Eur J Pharmacol. 2022 May 5:922:174914. PMID: 35337812

 

Categories: News

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only